HomeGeneticsConditionCerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy
Back to Condition
Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy

Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) is an inherited condition that causes stroke and other neurological impairments.

Overview

CARASIL is a rare inherited disorder that typically manifests in an individual's twenties or thirties. The condition is characterized by progressive neurological decline, including stroke, dementia, and movement disorders. Most affected individuals die within a decade of the onset of symptoms.

Symptoms

The signs and symptoms of CARASIL worsen slowly over time and include:

  • Muscle stiffness (spasticity) in the legs and walking difficulties.
  • Stroke or stroke-like episodes (occurring in about half of affected individuals before age 40).
  • Mood and personality changes.
  • Decline in thinking ability (dementia) and memory loss.
  • Premature hair loss (alopecia), often beginning in adolescence.
  • Attacks of low back pain caused by the degeneration of discs between the vertebrae.

Causes

CARASIL is caused by mutations in the HTRA1 gene. This gene provides instructions for making an enzyme that regulates signaling by proteins in the transforming growth factor-beta (TGF-β) family. In affected individuals, these mutations prevent effective regulation of TGF-β signaling, which is believed to alter the structure of small blood vessels in the brain (arteriopathy). These vascular abnormalities increase the risk of stroke and lead to the death of nerve cells (neurons).

Inheritance

This condition is inherited in an autosomal recessive pattern. This means that both copies of the gene in each cell must have mutations for the condition to occur. Parents of an affected individual typically carry one copy of the mutated gene but do not show signs or symptoms of the disorder.

Other Names

  • CARASIL
  • Familial young-adult-onset arteriosclerotic leukoencephalopathy with alopecia and lumbago without arterial hypertension
  • Maeda syndrome
  • Nemoto disease

Frequently Asked Questions

Currently, no specific drug targets the underlying arteriopathy. Management focuses on controlling vascular risk factors (blood pressure, cholesterol), using antiplatelet agents when appropriate, and providing physiotherapy to maintain mobility. Early intervention for back pain and careful monitoring for signs of stroke can improve quality of life, but the disease remains progressive.
Patients often notice low back pain that worsens with activity, sudden hair loss in the scalp during adolescence, and difficulty walking due to stiffness or spasticity in the legs. These symptoms can appear in the second or third decade of life and may precede more serious neurological events such as stroke or cognitive decline. Early recognition of these signs can prompt timely imaging and genetic testing.
MRI typically shows diffuse white matter hyperintensities in the periventricular and subcortical regions, often with a characteristic “pseudocystic” appearance. In addition, there may be thinning of the corpus callosum and microbleeds on susceptibility‑weighted imaging. Genetic confirmation of a pathogenic HTRA1 mutation is required to definitively diagnose CARASIL.
Because CARASIL is autosomal recessive, each parent is a carrier. Carrier testing can identify at-risk siblings. For future pregnancies, options include prenatal testing via chorionic villus sampling or amniocentesis, or preimplantation genetic diagnosis (PGD) with in‑vitro fertilization to select embryos without the HTRA1 mutation. Discussing these options with a genetics specialist can help families make informed decisions.===
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab